Vishal Kukreti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vishal Kukreti has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Christine Chen
Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
3 shared publicationsDonna E. Reece
Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
2 shared publicationsSuzanne Trudel
Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
2 shared publicationsVictor H. Jimenez‐Zepeda
Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
2 shared publications- Ahmed Rabea
Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt
1 shared publication Andrew Winter
Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
1 shared publication
Latest Publications
- Open Access
- 6 June 2012
- Published by Hindawi Limited in Case Reports in Hematology
- Vol. 2012, 1-3
Rituximab-Induced Coronary Vasospasm
Rituximab has improved the treatment of B-cell non-Hodgkin lymphomas. While it is generally well tolerated, serious adverse effects including infusion reactions with hemodynamic compromise and cardiac arrhythmias or ischemia are possible. We report a case of coronary vasospasm occurring during a rituximab infusion in a patient with minimal tumour burden and who had no cardiac risk factors. This case highlights that determination of the cause of ischemia is important and may identify some patients who can be successfully rechallenged.
- 6 June 2012
- Published by Hindawi Limited in Case Reports in Hematology
- Vol. 2012, 1-3
Open AccessRituximab-Induced Coronary Vasospasm
Rituximab has improved the treatment of B-cell non-Hodgkin lymphomas. While it is generally well tolerated, serious adverse effects including infusion reactions with hemodynamic compromise and cardiac arrhythmias or ischemia are possible. We report a case of coronary vasospasm occurring during a rituximab infusion in a patient with minimal tumour burden and who had no cardiac risk factors. This case highlights that determination of the cause of ischemia is important and may identify some patients who can be successfully rechallenged.
- Open Access
- 26 April 2012
- Published by Wiley in American Journal of Hematology
- Vol. 87 (8) , 822-823
Autologous stem cell transplant for light chain deposition disease: Incorporating bortezomib to the induction therapy
- 26 April 2012
- Published by Wiley in American Journal of Hematology
- Vol. 87 (8) , 822-823
Open AccessAutologous stem cell transplant for light chain deposition disease: Incorporating bortezomib to the induction therapy
- Open Access
- 27 June 2011
- Published by Wiley in American Journal of Hematology
- Vol. 86 (10) , 873-875
Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantation
High‐dose chemotherapy with autologous stem cell transplantation (ASCT) can achieve excellent clinical responses in patients with POEMS syndrome (Jimenez Zepeda et al., Blood 2010;116:2403; Gertz et al., Am J Hematol 2005;79:319–328; Gherardi et al., Ann Neurol 1994;35:501–505; Gattinoni et al., Nat Rev Immunol 2006;6:383–393; Salem et al., J Immunol 2009;182:2030–2040; Salem et al., Cancer Immunol Immunother 2010;59:341–353; Salem et al., Cell Immunol 2010;261:134–143). However, High‐dose melphalan with ASCT should be considered carefully due to its treatment‐related morbidity (Vuckovic et al., Blood 2003;101:2314–2317), especially in patients with poor performance status owing to polyneuropathy and multiorgan involvement, such as cardiac, respiratory, and renal failure. Significant increases in the concentration of circulating macrophage colony‐stimulating factor, erythropoietin, IL‐6, and TNF‐α, reach near maximal values at approximately day +12, predating neutrophil engraftment, and clinically manifest with fever, rash and edema (Dispenzieri et al., Eur J Haematol 2008;80:397–406). Depending on the definition used, ∼50% of patients satisfied criteria for engraftment syndrome (ES) (Vuckovic et al., Blood 2003;101:2314–2317). ES occurs in 27–47% of patients who undergo ASCT; mortality rate is reported from 8% to 18% (Gattinoni et al., Nat Rev Immunol 2006;6:383–393; Vuckovic et al., Blood 2003;101:2314–2317). We have therefore reviewed our experience with ASCT in patients with POEMS syndrome who were treated with cyclophosphamide and prednisone as induction therapy followed by cyclophosphamide mobilization with an emphasis on treatment‐related morbidity and frequency of ES. Our study confirms that ASCT is a feasible and efficacious treatment for patients with POEMS syndrome. In addition, the use of CP followed by cyclophosphamide mobilization decreases the incidence of PES leading to less morbidity and mortality rates. Am. J. Hematol. 2011.
- 27 June 2011
- Published by Wiley in American Journal of Hematology
- Vol. 86 (10) , 873-875
Open AccessCyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantation
High‐dose chemotherapy with autologous stem cell transplantation (ASCT) can achieve excellent clinical responses in patients with POEMS syndrome (Jimenez Zepeda et al., Blood 2010;116:2403; Gertz et al., Am J Hematol 2005;79:319–328; Gherardi et al., Ann Neurol 1994;35:501–505; Gattinoni et al., Nat Rev Immunol 2006;6:383–393; Salem et al., J Immunol 2009;182:2030–2040; Salem et al., Cancer Immunol Immunother 2010;59:341–353; Salem et al., Cell Immunol 2010;261:134–143). However, High‐dose melphalan with ASCT should be considered carefully due to its treatment‐related morbidity (Vuckovic et al., Blood 2003;101:2314–2317), especially in patients with poor performance status owing to polyneuropathy and multiorgan involvement, such as cardiac, respiratory, and renal failure. Significant increases in the concentration of circulating macrophage colony‐stimulating factor, erythropoietin, IL‐6, and TNF‐α, reach near maximal values at approximately day +12, predating neutrophil engraftment, and clinically manifest with fever, rash and edema (Dispenzieri et al., Eur J Haematol 2008;80:397–406). Depending on the definition used, ∼50% of patients satisfied criteria for engraftment syndrome (ES) (Vuckovic et al., Blood 2003;101:2314–2317). ES occurs in 27–47% of patients who undergo ASCT; mortality rate is reported from 8% to 18% (Gattinoni et al., Nat Rev Immunol 2006;6:383–393; Vuckovic et al., Blood 2003;101:2314–2317). We have therefore reviewed our experience with ASCT in patients with POEMS syndrome who were treated with cyclophosphamide and prednisone as induction therapy followed by cyclophosphamide mobilization with an emphasis on treatment‐related morbidity and frequency of ES. Our study confirms that ASCT is a feasible and efficacious treatment for patients with POEMS syndrome. In addition, the use of CP followed by cyclophosphamide mobilization decreases the incidence of PES leading to less morbidity and mortality rates. Am. J. Hematol. 2011.
- 29 June 2010
- Published by Wiley in American Journal of Hematology
- Vol. 85 (10) , 805-808
Two distinct syndromes of lymphoma associated AL amyloidosis: A case series and review of the literature
Light chain (AL) amyloidosis has a rare association with non-Hodgkin lymphoma (NHL). Both peritumoral and systemic AL amyloidosis have been reported, but a detailed description of these syndromes is lacking. We describe 10 patients with lymphoma associated AL amyloidosis. NHL patients with peritumoral amyloidosis had low or undetectable levels of monoclonal (M) protein, mostly single organ involvement(lung or soft tissue), and underlying extranodal marginal zone lymphoma, mucosa associated lymphoid tissue subtype. NHL patients with systemic amyloidosis had high levels of M-protein, multiorgan involvement with frequent cardiac involvement, and predominantly underlying lymphoplasmacytic lymphoma. Systemic amyloidosis was associated with inferior outcomes
- 29 June 2010
- Published by Wiley in American Journal of Hematology
- Vol. 85 (10) , 805-808
Two distinct syndromes of lymphoma associated AL amyloidosis: A case series and review of the literature
Light chain (AL) amyloidosis has a rare association with non-Hodgkin lymphoma (NHL). Both peritumoral and systemic AL amyloidosis have been reported, but a detailed description of these syndromes is lacking. We describe 10 patients with lymphoma associated AL amyloidosis. NHL patients with peritumoral amyloidosis had low or undetectable levels of monoclonal (M) protein, mostly single organ involvement(lung or soft tissue), and underlying extranodal marginal zone lymphoma, mucosa associated lymphoid tissue subtype. NHL patients with systemic amyloidosis had high levels of M-protein, multiorgan involvement with frequent cardiac involvement, and predominantly underlying lymphoplasmacytic lymphoma. Systemic amyloidosis was associated with inferior outcomes